Biora Therapeutics, Inc.
BIOR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.7% | -75.5% | -98.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 100% | 100% | -25.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,678,575% | -20,256.1% | -9,449.6% | -144.8% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,102,875% | -12,510.5% | -14,316% | -259.1% |
| EPS | -78.7 | -6.4 | -46.42 | -86.3 |
| % Growth | -1,129.7% | 86.2% | 46.2% | – |
| EPS Diluted | -78.7 | -6.4 | -46.42 | -86.3 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,851,350% | -12,246.9% | -13,197% | -142.9% |